… Using the developed model, we were able to show that … Monitoring of an eculizumab
concentration or classical pathway … In case monitoring of eculizumab concentrations or classical …

… and management of atypical hemolytic uremic syndrome (… aHUS has been established as
a prototypic disease resulting … of C5 blockade in the treatment of this devastating disease. C5 …

… An international consensus approach to the management of atypical hemolytic uremic
syndrome in children. Pediatric Nephrology. 2016;31(1):15-39 and Fakhouri F, Zuber J, Fremeaux-…

… The study was conducted in a one compartment model with nine patients receiving …
Monitoring of eculizumab therapy and complement activity in atypical hemolytic uremic syndrome …

… , monitoring drug safety, and measuring quality of care in a … of aHUS irrespective of
management choice or presence of … Cox proportional hazards regression models (hazard ratios …

… microangiopathy in animal models. Taken together, these observations highlight the
importance of endothelial cell health and indicate potential targets in the management of patients …

… Mice were weighed every 24 h and scored every 12 h (acute model) or 8 h (subacute model)
to monitor disease progression. To prevent the severe dehydration observed in the dose-…

… current treatment protocol is based on restrictive use of eculizumab. Prospective monitoring
… Following their model, it would be possible to extend the interval to 4 weeks in patients less …

… in atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs
2 weeks, respectively). Treatment choice … of ravulizumab and eculizumab for treating aHUS. …

… This study will include all aHUS patients and will monitor and evaluate the restrictive
treatment regimen according to the new Dutch guideline. With the CUREiHUS study we hope to …